about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusMembrane transporters in drug developmentCentral nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity.Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport.Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.PhRMA white paper on ADME pharmacogenomics.Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.Understanding the transport properties of metabolites: case studies and considerations for drug development.Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates.Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier.The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.Preparation, characterization and biological properties of biotinylated derivatives of calmodulinDevelopmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain.Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.Developmental expression of neuronal calmodulin-binding proteins in rat brain.Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialAssessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studiesToxicokinetics and toxicity of atorvastatin in dogsDisease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
P50
Q21195757-D2381777-3E67-472D-86F9-F09C3656376EQ29616802-501B071C-9B83-4689-9301-9E33F5813FFCQ34507518-6A4A7A03-D58C-4B99-B0D2-764081D962CBQ35086229-B5B4DB36-E066-4265-84EB-5B90AE7E28A3Q36371783-C8A71925-C52A-484D-A9FE-00A4AD1EC2B0Q36803379-4391DA5E-E94F-47BB-9056-FE800F32C5D7Q36929947-49F6AB85-65A8-4A0F-B1A8-82C9317D9464Q37182212-D37D78E3-C0A0-456E-A0E3-3E3E47E7D4CEQ38099191-132B45FC-6814-44FB-A0EE-9EC2E62B075DQ38172011-DCAFC32D-B1C2-412A-9FD1-ED3217261E1BQ38317835-7BEA241C-BA1C-4F10-8F72-41CA8EED148AQ39778869-2FB04B7F-1098-43F9-819C-4B075AE3C38BQ40021112-7D03C9FC-A871-4221-B996-C2DD50A12B79Q40060557-7129D20E-3C48-47FB-B074-23B3E178D89DQ40194002-1A217DC0-E718-445A-B7A6-35BEF455B6CAQ40313295-50A69242-1F81-41F4-8903-3CF66E80ABA5Q40321269-DDE0340D-C1ED-40A2-A209-C9E211FE5137Q40518962-FF0C3393-C2A0-4478-B227-46DD8CBB1C32Q40538777-969BCACD-292C-4211-AC2E-2E612D9EA23EQ40543746-DD4CE149-89EA-4946-992E-C094D0D337DCQ40582582-F7768A2D-5481-4912-B36B-E825C96F4856Q40632654-12850E21-94CB-4F24-A350-EA9DE58A5077Q40689125-2E874217-4B52-46A2-9832-7037AE48DF1BQ41015337-FF27CEF8-3226-4951-A808-EBD65359F7AEQ42714414-F285DD4F-F8DB-4434-9FE0-3C5A2DEE7B41Q42860081-A4D7D254-7D48-4F30-8710-D1210E263C87Q44928642-544442A7-2051-4B90-BC92-03170F173D11Q46463079-13E1EF5B-FDCB-4C9E-8269-991ABCE42739Q49027753-497493F1-F86C-4EE7-9198-8FCBAF9F5739Q73092542-F72B4A0D-D3B6-446D-A833-BE316BAFD7DFQ84696507-1507B529-36E6-408E-81F8-EA7D0C9146D6Q86194319-F12413A9-FAB3-4438-9134-24AA6E956C81Q88657543-84DA69DA-4407-4243-9184-355FAA402A2B
P50
description
researcher ORCID ID = 0000-0003-3812-8985
@en
wetenschapper
@nl
name
Joseph W Polli
@ast
Joseph W Polli
@en
Joseph W Polli
@es
Joseph W Polli
@nl
type
label
Joseph W Polli
@ast
Joseph W Polli
@en
Joseph W Polli
@es
Joseph W Polli
@nl
prefLabel
Joseph W Polli
@ast
Joseph W Polli
@en
Joseph W Polli
@es
Joseph W Polli
@nl
P1153
7005889947
P31
P496
0000-0003-3812-8985